tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jun 29;13(1):10583.
doi: 10.1038/s41598-023-36342-7. Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
Shailima Rampogu[SUP] 1 [/SUP], Tae Sung Jung[SUP] 2 [/SUP], Min Woo Ha[SUP] 3 [/SUP], Keun Woo Lee[SUP] 4 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) is a recent pandemic that caused serious global emergency. To identify new and effective therapeutics, we employed a drug repurposing approach. The poly (ADP ribose) polymerase inhibitors were used for this purpose and were repurposed against the main protease (Mpro) target of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). The results from these studies were used to design compounds using the 'Grow Scaffold' modules available on Discovery Studio v2018. The three designed compounds, olaparib 1826 and olaparib 1885, and rucaparib 184 demonstrated better CDOCKER docking scores for Mpro than their parent compounds. Moreover, the compounds adhered to Lipinski's rule of five and demonstrated a synthetic accessibility score of 3.55, 3.63, and 4.30 for olaparib 1826, olaparib 1885, and rucaparib 184, respectively. The short-range Coulombic and Lennard-Jones potentials also support the potential binding of the modified compounds to Mpro. Therefore, we propose these three compounds as novel SARS-CoV-2 inhibitors.
. 2023 Jun 29;13(1):10583.
doi: 10.1038/s41598-023-36342-7. Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
Shailima Rampogu[SUP] 1 [/SUP], Tae Sung Jung[SUP] 2 [/SUP], Min Woo Ha[SUP] 3 [/SUP], Keun Woo Lee[SUP] 4 [/SUP]
Affiliations
- PMID: 37386052
- DOI: 10.1038/s41598-023-36342-7
Coronavirus disease 2019 (COVID-19) is a recent pandemic that caused serious global emergency. To identify new and effective therapeutics, we employed a drug repurposing approach. The poly (ADP ribose) polymerase inhibitors were used for this purpose and were repurposed against the main protease (Mpro) target of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). The results from these studies were used to design compounds using the 'Grow Scaffold' modules available on Discovery Studio v2018. The three designed compounds, olaparib 1826 and olaparib 1885, and rucaparib 184 demonstrated better CDOCKER docking scores for Mpro than their parent compounds. Moreover, the compounds adhered to Lipinski's rule of five and demonstrated a synthetic accessibility score of 3.55, 3.63, and 4.30 for olaparib 1826, olaparib 1885, and rucaparib 184, respectively. The short-range Coulombic and Lennard-Jones potentials also support the potential binding of the modified compounds to Mpro. Therefore, we propose these three compounds as novel SARS-CoV-2 inhibitors.